Cargando…
The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advance...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475579/ https://www.ncbi.nlm.nih.gov/pubmed/32944347 http://dx.doi.org/10.21037/jtd-20-2137 |
_version_ | 1783579537228955648 |
---|---|
author | Zhang, Tao Bi, Nan Zhou, Zongmei Chen, Dongfu Feng, Qinfu Liang, Jun Xiao, Zefen Hui, Zhouguang Lv, Jima Wang, Xin Deng, Lei Wang, Wenqing Liu, Wenyang Wang, Jianyang Zhai, Yirui Wang, Luhua |
author_facet | Zhang, Tao Bi, Nan Zhou, Zongmei Chen, Dongfu Feng, Qinfu Liang, Jun Xiao, Zefen Hui, Zhouguang Lv, Jima Wang, Xin Deng, Lei Wang, Wenqing Liu, Wenyang Wang, Jianyang Zhai, Yirui Wang, Luhua |
author_sort | Zhang, Tao |
collection | PubMed |
description | BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advanced NSCLC. METHODS: The data of patients with unresectable locally advanced NSCLC who were treated with radiotherapy (RT), sequential chemoradiotherapy, or concurrent chemoradiotherapy between January, 2013, and December, 2017, in our institution were retrospectively reviewed and analyzed. Student’s t-test and χ(2) test were used to evaluate the differences between groups divided by optimal cutoff. Survival rates were calculated using the Kaplan-Meier method, and multivariate cox regression was performed to determine the prognostic factors for survival outcomes. RESULTS: A total of 749 patients were included in this analysis. Based on the optimal cutoff, the patients were stratified into two age groups: <65 years old (the younger group, n=482) and ≥65 years old (the older group, n=267). The older group had more patients with poor Karnofsky Performance Score (KPS), squamous cell sarcoma (SCC), and IIIA stage than the younger group. The older patients were more likely to have received RT alone (40.1%) and less likely to have received concurrent chemoradiotherapy (cCRT) (26.6%) than the younger patients (8.1% and 54.8%, respectively, P<0.001). The median overall survival (OS) was 33 months (95% CI: 29–37 months) and 21 months (95% CI: 18–27 months) for the younger group and the older group, respectively (P<0.001). Multivariate Cox regression analysis showed that age had a significant independent association with OS (HR, 1.25; 95% CI: 1.01–1.55) after adjustment for covariates. The incidences of RP, symptomatic RP, and severe RP were similar between the two groups, but the incidence of fatal RP was higher in the older group (4.5% vs. 1.7%, P=0.039). CONCLUSIONS: The clinical characteristics of the older patients in our study differed from those of the younger patients, and the older patients were more likely to choose conservative treatment. OS was longer in the older patients and more cases of fatal RP occurred in the older group. |
format | Online Article Text |
id | pubmed-7475579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-74755792020-09-16 The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy Zhang, Tao Bi, Nan Zhou, Zongmei Chen, Dongfu Feng, Qinfu Liang, Jun Xiao, Zefen Hui, Zhouguang Lv, Jima Wang, Xin Deng, Lei Wang, Wenqing Liu, Wenyang Wang, Jianyang Zhai, Yirui Wang, Luhua J Thorac Dis Original Article BACKGROUND: Chemoradiotherapy is the recommended treatment for patients with unresectable locally advanced non-small cell lung cancer (NSCLC). This study aimed to determine the impact of age on the survival outcomes and risk of radiation pneumonitis (RP) in patients with unresectable locally advanced NSCLC. METHODS: The data of patients with unresectable locally advanced NSCLC who were treated with radiotherapy (RT), sequential chemoradiotherapy, or concurrent chemoradiotherapy between January, 2013, and December, 2017, in our institution were retrospectively reviewed and analyzed. Student’s t-test and χ(2) test were used to evaluate the differences between groups divided by optimal cutoff. Survival rates were calculated using the Kaplan-Meier method, and multivariate cox regression was performed to determine the prognostic factors for survival outcomes. RESULTS: A total of 749 patients were included in this analysis. Based on the optimal cutoff, the patients were stratified into two age groups: <65 years old (the younger group, n=482) and ≥65 years old (the older group, n=267). The older group had more patients with poor Karnofsky Performance Score (KPS), squamous cell sarcoma (SCC), and IIIA stage than the younger group. The older patients were more likely to have received RT alone (40.1%) and less likely to have received concurrent chemoradiotherapy (cCRT) (26.6%) than the younger patients (8.1% and 54.8%, respectively, P<0.001). The median overall survival (OS) was 33 months (95% CI: 29–37 months) and 21 months (95% CI: 18–27 months) for the younger group and the older group, respectively (P<0.001). Multivariate Cox regression analysis showed that age had a significant independent association with OS (HR, 1.25; 95% CI: 1.01–1.55) after adjustment for covariates. The incidences of RP, symptomatic RP, and severe RP were similar between the two groups, but the incidence of fatal RP was higher in the older group (4.5% vs. 1.7%, P=0.039). CONCLUSIONS: The clinical characteristics of the older patients in our study differed from those of the younger patients, and the older patients were more likely to choose conservative treatment. OS was longer in the older patients and more cases of fatal RP occurred in the older group. AME Publishing Company 2020-08 /pmc/articles/PMC7475579/ /pubmed/32944347 http://dx.doi.org/10.21037/jtd-20-2137 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zhang, Tao Bi, Nan Zhou, Zongmei Chen, Dongfu Feng, Qinfu Liang, Jun Xiao, Zefen Hui, Zhouguang Lv, Jima Wang, Xin Deng, Lei Wang, Wenqing Liu, Wenyang Wang, Jianyang Zhai, Yirui Wang, Luhua The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title | The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title_full | The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title_fullStr | The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title_full_unstemmed | The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title_short | The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
title_sort | impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475579/ https://www.ncbi.nlm.nih.gov/pubmed/32944347 http://dx.doi.org/10.21037/jtd-20-2137 |
work_keys_str_mv | AT zhangtao theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT binan theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT zhouzongmei theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT chendongfu theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT fengqinfu theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT liangjun theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT xiaozefen theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT huizhouguang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT lvjima theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangxin theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT denglei theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangwenqing theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT liuwenyang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangjianyang theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT zhaiyirui theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangluhua theimpactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT zhangtao impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT binan impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT zhouzongmei impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT chendongfu impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT fengqinfu impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT liangjun impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT xiaozefen impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT huizhouguang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT lvjima impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangxin impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT denglei impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangwenqing impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT liuwenyang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangjianyang impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT zhaiyirui impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy AT wangluhua impactofageonthesurvivaloutcomesandriskofradiationpneumonitisinpatientswithunresectablelocallyadvancednonsmallcelllungcancerreceivingchemoradiotherapy |